Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.

Takano EA, Mitchell G, Fox SB, Dobrovic A.

BMC Cancer. 2008 Feb 25;8:59. doi: 10.1186/1471-2407-8-59.

2.

Determinants of RNA quality from FFPE samples.

von Ahlfen S, Missel A, Bendrat K, Schlumpberger M.

PLoS One. 2007 Dec 5;2(12):e1261.

4.

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.

Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH.

Lung Cancer. 2008 Jan;59(1):111-8.

PMID:
17904685
6.

Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90.

7.

High resolution melting for mutation scanning of TP53 exons 5-8.

Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ; Australian Ovarian Cancer Study Group., DeFazio A, Fox SB, Brenton JD, Bowtell DD, Dobrovic A.

BMC Cancer. 2007 Aug 31;7:168.

8.
9.

High-resolution DNA melting analysis for simple and efficient molecular diagnostics.

Reed GH, Kent JO, Wittwer CT.

Pharmacogenomics. 2007 Jun;8(6):597-608. Review.

PMID:
17559349
11.

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.

Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, Takigawa N, Tabata M, Takata M, Kiura K, Tanimoto M.

Cancer Sci. 2007 Mar;98(3):357-63.

13.

Detection of epidermal growth factor receptor variations by partially denaturing HPLC.

Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, Ahmad B, Lee SC, Goh BC, Kawakami K, Segal A, Iacopetta B, Soong R.

Clin Chem. 2007 Jan;53(1):62-70.

14.

Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.

Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada NA, Miller WH Jr, Chong G.

Cancer. 2006 Dec 15;107(12):2858-65.

15.

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.

van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P.

Ann Oncol. 2007 Jan;18(1):99-103.

PMID:
17060486
16.

The epidermal growth factor receptor pathway: a model for targeted therapy.

Scaltriti M, Baselga J.

Clin Cancer Res. 2006 Sep 15;12(18):5268-72. Review.

17.

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.

Nomoto K, Tsuta K, Takano T, Fukui T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y, Matsuno Y.

Am J Clin Pathol. 2006 Oct;126(4):608-15.

PMID:
16938658
18.

EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K, Osada H, Imaizumi K, Hasegawa Y, Shimokata K, Sekido Y.

Cancer Sci. 2006 Aug;97(8):753-9.

20.

BRAF and c-kit gene copy number in mutation-positive malignant melanoma.

Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ.

Hum Pathol. 2006 May;37(5):520-7.

PMID:
16647948
Items per page

Supplemental Content

Support Center